Clinical trial NCT00869687: Biopsy Study for Sculptra (Poly-L-Lactic Acid)
Official title: A Single Group Study for the Characterization of Human Tissue Response to Injectable Poly-L-Lactic Acid (Sculptra) in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Volunteers
Lead sponsor: Bausch Health Americas, Inc.
Sponsor class: INDUSTRY
First posted: 2009-03-26
Enrollment: 14
Sex: ALL
Minimum age (years): 35
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The primary objective of this study involves research to evaluate new collagen (the elastic fibers that provide skin with its strength and resilience) formation in the skin following injections of Sculptra (Poly-L-Lactic Acid or PLLA). The secondary objectives of the study are to better understand the human skin responses to Sculptra and to assess the safety of Sculptra injections.


Eligibility criteria: Inclusion Criteria:

* If female, the subject must use appropriate form of birth control.

Exclusion Criteria:

* History of allergies or an allergic reaction to local numbing medications (e.g., lidocaine, etc.), latex, or silicone.
* History of forming large scars following an accident or surgery.
* History of any bleeding problems.
* Redness, swelling, or signs of infection behind the right or left ear between the area of the earlobe and hairline.
* Pimples, rashes, scarring or any other skin changes behind the right or left ear between the area of the earlobe and hairline.
* History of any medical problems (for example, heart attack, stroke, diabetes/high blood sugar, hepatitis, human immunodeficiency virus (HIV), severe asthma, rheumatoid arthritis, emphysema, breathing problems). Subjects with high blood pressure or high cholesterol may qualify for the study if there have been no changes in their medications for three (3) months.
* History of cancer within five (5) years.
* Previous cosmetic surgery or cosmetic procedures affecting the area behind the ear.
* Subject who plans to have any facial or ear surgery within the next year.
* History of alcohol or drug abuse.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: Biopsies change from baseline to 6 months after first Sculptra injection in level of Type 1 collagen.
timeFrame: 6 months
Secondary outcomes:
measure: Change from baseline in level of Type 1 collagen at 3 months and 12 months
timeFrame: 3 and 12 months
measure: Change from baseline in level of Type III collagen at 3 months, 6 months, & 12 months by immunohistochemistry in a central laboratory.
timeFrame: 3, 6, and 12 months
measure: Qualitative assessment in degree of change from baseline in Type I collagen at 3 months, 6 months, & 12 months by a pathologist.
timeFrame: 3, 6, and 12 months
measure: Degree of inflammation assessed by histology at 3 months, 6 months, and 12 months.
timeFrame: 3, 6, and 12 months
measure: Qualitative assessment in degree of change from baseline in Type III collagen at 3 months, 6 months, & 12 months by a pathologist.
timeFrame: 3, 6, and 12 months
Other outcomes:
Locations:
city: Laval
country: Canada
facility: Sanofi-Aventis Administrative Office
Study officials:
affiliation: Sanofi
name: Tara Semanchik, MBA
role: STUDY_DIRECTOR
References: